ASAloysious Ssemaganda

Aloysious Ssemaganda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aloysious Ssemaganda has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted Metagenomics Reveals Hidden Chickenpox Epidemic Amid Mpox Surveillance in Uganda

    by Stephen Kanyerezi, Alisen Ayitewala, Jupiter Marina Kabahita, Hellen Rosette Oundo, Julius Seruyange, Wilson Tenywa, Godwin Tusabe, Stacy Were, Moses Murungi, Martha Nabukyu, et al.

    In regions where both Mpox virus (MPXV) and varicella zoster virus (VZV) are co-circulating, overlapping clinical manifestations can complicate clinical diagnosis. During the MPXV outbreak declared in Uganda on July, 2024, symptomatic suspected cases tested PCR negative for Mpox. To determine the cause of symptoms, we employed metagenomic sequencing with a targeted Viral Surveillance panel in 284 Mpox negative samples. VZV was identified as the predominant pathogen in 86% of MPXV-negative cases, suggesting a concurrent chickenpox surge. Using the VaricellaGen pipeline for variant calling, clade typing, and phylogeny, 118 (42%) samples that achieved ≥70% genome coverage were of clade 5 based on the single-nucleotide polymorphism (SNP) dataset. This data confirms co-circulation of chickenpox during the Mpox outbreak in Uganda. Our results underscore the need for laboratory confirmation of Mpox and the inclusion of VZV in the testing algorithm during the Mpox outbreak.

  • Open Access

    The epidemiology of antibiotic-resistant clinical pathogens in Uganda

    by Ritah Namusoosa, Ibrahim Mugerwa, Keneth Iceland Kasozi, Allan Muruta, Grace Najjuka, Winifred D Atuhaire, Susan Nabadda, Henry Mwebesa, Charles Olaro, Isaac Ssewanyana, et al.

    Antibiotic resistance (ABR) is a phenomenon where bacteria become unresponsive to antibiotics, and globally, it is estimated to cause 1.27 million deaths [1]. This disproportionately affects people living in sub-Saharan Africa, where 27.3 deaths per 100 000 population lose their lives due to hard-to-treat infections [2]. Vulnerable populations, including neonates, infants, and pregnant mothers, bear the […]


  • Open Access

    Sharpley Additive Explanations for Viral Rebound Prediction in Patients on Antiretroviral Therapy

    by Ssenoga Badru, Muhire Jacob, Joyce Nakatumba-Nabende, Aloysious Ssemaganda, Ggaliwango Marvin

    Although Antiretroviral Therapy (ART) is an effective treatment for Human Immunodeficiency Virus (HIV) infection, pro-viral HIV-DNA remains in target cells of the body, preventing ART from curing Acquired Immunodeficiency Syndrome (AIDS) of the patient, a disease caused by HIV. In order to prevent HIV reactivation from persistent viral reservoirs, ART is necessary. When an HIV positive patient takes ART as directed by a medical professional and does not suppress after a second viral load test but had suppressed in the previous viral load test, this is known as HIV Viral Rebound(VR). Viral rebound increases the likelihood of treatment failure, resistance to ART, vulnerability to other infections among other challenges. In this research, we developed CatBoost, XgBoost and Light GBM Machine Learning (ML) models that predicted HIV positive patients with viral rebound using healthcare facilities, laboratory data, clinical and demographic information. This paper focused on one Explainable Artificial Intelligence (XAI) technique, SHAP (SHarpley Additive exPlanations) values that is used to explain a model’s output. Interpretability and transparency in ML algorithms are improved by this technique, which also helps to better understand which features have the greatest influence on predictions and helps to comprehend the decision-making process of models. After data pre-processing, the dataset was split up in portions of 70%, 15% and 15% to train, validate and test the ML models respectively. We confirmed that Light GBM performed best on test data with f1-score mean of 0.92. We also highlighted viral rebound feature interaction for the patients and makes it possible for medical professionals to understand prediction results accurately based on SHAP, foster proper user trust, and offer guidance on how to enhance a model.

  • Open Access

    Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study

    by Annemarie Namuniina, Enoch S. Muyanja, Victoria M. Biribawa, Brenda A. Okech, Aloysious Ssemaganda, Matt A. Price, Nancy Hills, Ann Nanteza, Bernard Ssentalo Bagaya, Daniela Weiskopf, et al.

    The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world. In particular, multiple countries in East, Central, and West Africa had significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, an exploratory study of stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015–2017 prior to the COVID-19 pandemic (n = 29) and from hospitalized Ugandan COVID-19 patients (n = 3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population, however this may be in part due to the limited sample size examined. The rates of cross-reactive T-cell populations in this exploratory Ugandan population appears higher than previous estimates from resource-rich countries like the United States (20–50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward.


  • Open Access

    High proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses

    by Annemarie Namuniina, Enoch S Muyanja, Victoria M Biribawa, Brenda A Okech, Aloysious Ssemaganda, Matt A Price, Nancy Hills, Ann Nanteza, Bernard Ssentalo Bagaya, Daniela Weiskopf, et al.

    The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world with multiple countries in East, Central, and West Africa having significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015-2017 prior to the COVID-19 pandemic (n=29) and from hospitalized Ugandan COVID-19 patients (n=3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population. The rates of cross-reactive T-cell populations in these Ugandans is higher than previous estimates from resource-rich countries like the United States (20-50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward.


  • Open Access

    Expansion of cytotoxic tissue-resident CD8+ T cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19 vaccination

    by Aloysious Ssemaganda, Huong Mai Nguyen, Faisal Nuhu, Naima Jahan, Catherine M. Card, Sandra Kiazyk, Giulia Severini, Yoav Keynan, Ruey-Chyi Su, Hezhao Ji, et al.

    Vaccines against SARS-CoV-2 have shown high efficacy in clinical trials, yet a full immunologic characterization of these vaccines, particularly within the human upper respiratory tract, is less well known. Here, we enumerate and phenotype T cells in nasal mucosa and blood using flow cytometry before and after vaccination with the Pfizer-BioNTech COVID-19 vaccine (n = 21). Tissue-resident memory (Trm) CD8+ T cells expressing CD69+CD103+ increase in number ~12 days following the first and second doses, by 0.31 and 0.43 log10 cells per swab respectively (p = 0.058 and p = 0.009 in adjusted linear mixed models). CD69+CD103+CD8+ T cells in the blood decrease post-vaccination. Similar increases in nasal CD8+CD69+CD103− T cells are observed, particularly following the second dose. CD4+ cells co-expressing CCR6 and CD161 are also increased in abundance following both doses. Stimulation of nasal CD8+ T cells with SARS-CoV-2 spike peptides elevates expression of CD107a at 2- and 6-months (p = 0.0096) post second vaccine dose, with a subset of donors also expressing increased cytokines. These data suggest that nasal T cells may be induced and contribute to the protective immunity afforded by this vaccine.


  • Mannosylated liposomes formulated with whole parasite P. falciparum blood-stage antigens are highly immunogenic in mice

    by Aloysious Ssemaganda, Ashwini Kumar Giddam, Leanne M. Low, Xue Q. Liu, Mei-Fong Ho, Mehfuz Zaman, Waleed M. Hussein, Mariusz Skwarczynski, Istvan Toth, Danielle I. Stanisic, et al.


  • Open Access

    Gold(i) phosphine compounds as parasite attenuating agents for malaria vaccine and drug development

    by Aloysious Ssemaganda, Leanne M. Low, Krista R. Verhoeft, Mathias Wambuzi, Barbarah Kawoozo, Sharon B. Nabasumba, Juliet Mpendo, Bernard S. Bagaya, Noah Kiwanuka, Danielle I. Stanisic, et al.

    The asexual blood-stagePlasmodiumparasite attenuating properties of gold(i) phosphine compounds are exploited in a novel strategy for malaria vaccine development.


  • Open Access

    Low prevalence of laboratory-confirmed malaria in clinically diagnosed adult women from the Wakiso district of Uganda

    by Sergey Yegorov, Ronald M. Galiwango, Aloysious Ssemaganda, Moses Muwanga, Irene Wesonga, George Miiro, David A. Drajole, Kevin C. Kain, Noah Kiwanuka, Bernard S. Bagaya, et al.

    The malaria burden in sub-Saharan Africa (SSA) has fallen substantially. Nevertheless, malaria remains a serious health concern, and Uganda ranks third in SSA in total malaria burden. Epidemiological studies of adult malaria in Uganda are scarce and little is known about rates of malaria in non-pregnant adult women. This pilot study assessed malaria prevalence among adult women from Wakiso district, historically a highly malaria endemic region. Adult women using public health services were screened for malaria, HIV and pregnancy. A physician-selected subset of women presenting to the Outpatient Department of Entebbe General Hospital (EGH) with current fever (axillary temperature ≥37.5 °C) or self-reporting fever during the previous 24 h, and a positive thick smear for malaria in the EGH laboratory were enrolled (n = 86). Women who self-identified as pregnant or HIV-positive were excluded from screening. Malaria infection was then assessed using HRP2/pLDH rapid diagnostic tests (RDTs) in all participants. Repeat microscopy and PCR were performed at a research laboratory for a subset of participants. In addition, 104 women without a history of fever were assessed for asymptomatic parasitaemia using RDT, and a subset of these women screened for parasitaemia using microscopy (40 women) and PCR (40 women). Of 86 women diagnosed with malaria by EGH, only two (2.3%) had malaria confirmed using RDT, subsequently identified as a Plasmodium falciparum infection by research microscopy and PCR. Subset analysis of hospital diagnosed RDT-negative participants detected one sub-microscopic infection with Plasmodium ovale. Compared to RDT, sensitivity, specificity and PPV of hospital microscopy were 100% (CI 19.8–100), 0% (CI 0–5.32) and 2.33% (CI 0.403–8.94) respectively. Compared to PCR, sensitivity, specificity and PPV of hospital microscopy were 100% (CI 31.0–100), 0% (CI 0–34.5) and 23.1% (CI 6.16–54.0), respectively. No malaria was detected among asymptomatic women using RDT, research microscopy or PCR. Malaria prevalence among adult women appears to be low in Wakiso, but is masked by high rates of malaria overdiagnosis. More accurate malaria testing is urgently needed in public hospitals in this region to identify true causes of febrile illness and reduce unnecessary provision of anti-malarial therapy.